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AbStrAct
introduction: The aims of this study were to assess the impact of isonatraemic haemodialysis on reduction of 
interdialytic weight gain (IDWG) and blood pressure (BP) as well as its tolerability in our study population.
Methods: This crossover trial, at the Aristide Le Dantec University Hospital in Senegal, was conducted on 32 patients 
with kidney failure who were stable on treatment with chronic haemodialysis. In the initial “control phase”, patients 
had nine haemodialysis sessions with a dialysate sodium (Na+) concentration (Na+ dialysate) of 138 mmol/L. The 
serum Na+ set point (SP) for each patient was calculated from three predialytic mid-week values. In the second 
phase, the “individualized phase”, patients had nine haemodialysis sessions with Na+ dialysate equal to their SP. 
results: The mean age of the patients was 55.5 ± 12.1 years, with a male/female ratio of 1.3 and the most common 
cause of kidney disease was hypertension (47%). Mean predialytic serum Na+ concentration was 135.8 ± 1.9 
mmol/L, with a mean intra-individual coefficient of variation of 2%. Mean interdialytic weight gain (IDWG) was 1.9 
kg and 1.8 kg in the control and individualized phases, respectively (P = 0.75). A reduction in postdialytic systolic 
blood pressure (BP) was observed during the individualized phase (P = 0.04). A similar trend was noted in pre- and 
intradialytic BP but this was not statistically significant. Apart from headaches, which were more common in the 
individualized phase (P = 0.04), isonatraemic haemodialysis was well tolerated.
conclusions: IDWG as well as pre- and intradialytic BP were unaffected by isonatraemic haemodialysis. Postdialytic 
BP was significantly reduced.
introduction: Les objectifs de cette étude étaient d’évaluer l’impact de l’hémodialyse isonatrémique sur la réduction 
de la prise de poids inter-dialytique (PPID) et de la pression artérielle (PA) ainsi que sa tolérance dans notre 
population d’étude.
Méthodes: Cet essai croisé a été mené au centre hospitalier universitaire Aristide Le Dantec de Dakar (Sénégal) 
chez des patients hémodialysés chroniques. Durant la première phase dite « phase contrôle », les patients ont eu 
neuf séances d’hémodialyse avec une concentration de sodium dans le dialysat (Na+ dialysat) de 138 mmol/L. Le 
set-point (SP) de la natrémie a été calculé pour chaque patient et correspondait à la moyenne de 3 natrémies pré-
dialytiques en milieu de semaine. Durant la deuxième phase dite « phase individualisée », les patients ont eu neuf 
séances d’hémodialyse avec du Na+ dialysat égal à leur SP.
résultats: Trente-deux patients ont été inclus. L’âge moyen était de 55,5 ± 12,1 ans avec un ratio homme/femme 
de 1,3 et la néphropathie initiale la plus fréquente était l’hypertensive (47%). La natrémie pré-dialytique moyenne 
était de 135,8 ± 1,9 mmol/L, avec un coefficient de variation intra-individuel moyen de 2 %. La PPID moyenne était 
de 1,9 kg et 1,8 kg dans les phases de contrôle et individualisé, respectivement (P = 0,75). Une diminution de la 
PA systolique post-dialytique a été observée au cours de la phase individualisée (P = 0,04). Une tendance similaire 
sans significativité statistique a été notée sur les PA pré- et intra-dialytiques. Hormis les céphalées, plus fréquentes 
pendant la phase individualisée (P = 0,04), l’hémodialyse isonatrémique a été bien tolérée.
conclusions: La PPID, les PA pré- et intra-dialytiques n’ont pas été affectées par l’hémodialyse isonatrémique. La PA 
post-dialytique était significativement réduite.
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INtrODUctION
Chronic accumulation of sodium and water contributes 
to cardiovascular risk in patients with kidney failure who are 
being treated with maintenance haemodialysis. The volume 
overload is involved in the pathogenesis of hypertension, 
left ventricular hypertrophy (LVH) and sudden death 
[1-3]. Several strategies have been successfully imple-
mented to improve the salt and water status, such as 
sodium restriction [4,5], increasing the frequency and 
duration of haemodialysis sessions [6,7], volume manage-
ment using bioimpedance [8,9] and, more recently, indivi-
dualized prescription of the dialysis sodium concentration 
(Na+ dialysate) [10-12]. 
Isonatraemic haemodialysis has been shown to improve 
haemodynamic tolerance of the dialysis procedure in 
patients over 70 years [13]. There are several variations, 
including isonatraemic, isoconductive and isotonic haemo-
dialysis. Isonatraemic haemodialysis matches the Na+ 
dialysate to the patient’s average pre-dialysis serum Na+ 
concentrations, the “set point” (SP) [14]. In one study of 27 
patients, isonatraemic haemodialysis reduced interdialytic 
weight gain (IDWG). There were also improvements in 
thirst score, blood pressure (BP) control and decreased 
intradialytic hypotension [10]. 
To our knowledge, no previous work on isonatraemic 
haemodialysis or individualized Na+ dialysate prescription 
has been conducted in Senegal. This trial was performed to 
assess the impact of isonatraemic haemodialysis on the 
reduction of IDWG and BP.  We also aimed to assess its 
tolerability, focusing on intradialytic hypotension and 
cramping during haemodialysis sessions.
MEtHODS
A crossover trial was conducted at the Aristide Le Dantec 
University Hospital in Dakar, Senegal, from 1 April to 15 
May 2020, in patients with kidney failure who were stable 
on treatment with chronic haemodialysis. 
The study was performed in two phases: first, a “control 
phase”, during which patients had three weeks of 
haemodialysis (nine sessions of treatment) with a standard 
Na+ dialysate of 138 mmol/L. During this phase, the serum 
Na+ set point (SP) for each patient was calculated from 
three predialytic mid-week values, and the intra-individual 
variability and the coefficient of variation of natraemia were 
calculated [10]. All events occurring during haemodialysis 
sessions and those reported by the patient during the 
interdialytic periods were recorded. Na+ measurements 
used an ion-selective electrode (ARCHITECT ci410 
analyser, Abbott Laboratories).
In the second phase, the “individualized phase”, patients 
who had completed the control phase had three weeks of 
haemodialysis with a Na+ dialysate equal to their SP. 
Haemodialysis parameters and intra- and interdialytic 
events were again recorded. Intra-individual variability in 
serum Na+ concentrations were calculated by the dif-
ference between the minimum and the maximum 
concentrations for each patient. The coefficient of variation 
was equal to the ratio of the standard deviation to the 
mean of the serum Na+ concentration for each patient.
Patients were included if they were over 18 years of age, 
stable on chronic haemodialysis for more than three 
months, receiving three treatment sessions per week and 
had signed written informed consent. Diabetic patients, 
anyone who had a serious cardiovascular event in the 
preceding three months, and those using a temporary 
haemodialysis catheter or who had vascular access dys-
function were not included.
Data were captured using Microsoft Excel and analysed 
using R software version 4.03. Numerical variables were 
summarised using mean and standard deviation and 
categorical variables were summarised using counts and 
proportions. The control and individualized phases were 
compared using paired z tests and McNemar’s tests. A P 
value of <0.05 was considered statistically significant.
The study was approved by the Ethics Committee of the 
Department of Medicine of Cheikh Anta Diop University 
of Dakar (study registration number 033/2020/CER/
UCAD). All patients provided written, informed consent. 
The work was not supported by any external funding.
rESULtS
Of 100 patients on chronic haemodialysis at our centre, 60 
were included in the study. Only 32 had complete 
measurements and could be included in the analysis (Figure 
1). Their mean age was 55.5 ± 12.1 years, with a male/
female ratio of 1.3. Anaemia was noted in 22 patients 
(69%); 13 patients (41%) had haemoglobin concentrations 
between 9 g/dL and 11 g/dL and iron deficiency was noted 
in 7 patients (22%). Secondary hyperparathyroidism was 
present in 21 patients and vitamin D deficiency in 11 
patients. Cardiac ultrasound performed on 20 patients 
(63%) reported left ventricular hypertrophy in 18. The 
mean left ventricular ejection fraction was 65.3 ± 9.6%. 
Twenty-one patients (66%) were receiving antihyperten-
sive treatment (Table 1).
The mean serum Na+ concentration was 135.8 ± 1.9 
mmol/L, with a mean coefficient of variation of 2% and 
mean intra-individual variability of 4.6 ± 2.9 mmol/L. 
Sixty percent of predialytic measurements were between 
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Figure 1.  Study flow diagram.
100 patients on chronic haemodialysis
40 patients excluded
• 11 on irregular dialysis
• 9 did not consent
•  3 had a recent cardiovascular 
event
• 4 had diabetes mellitus
• 5 had poor vascular access






135 mmol/L and 139 mmol/L (Figure 2). Set points between 
135 mmol/L and 136 mmol/L were the most common (13 
patients, 41%). See Figure 3. 
The mean serum potassium concentration was 4.3 ± 
0.9 mmol/L. Sixty-nine percent of patients had a serum 
potassium concentration between 4.0 mmol/L and 5.0 
mmol/L. Hyperkalaemia was noted in 11%.
The mean ultrafiltration (UF) volume was slightly higher 
in the control phase, but this was not statistically significant 
(1.9 L vs 1.8 L; P = 0.70). The mean IDWG was 1.9 kg vs 
1.8 kg in the control and individualized phases, respectively 
(P = 0.75). A significant reduction in postdialytic systolic 
BP was observed during the individualized phase (148 
mmHg vs 135 mmHg; P = 0.04). This trend was also 
observed with the pre- and intradialytic BP without 
reaching statistical significance (Table 2). 
Qualitative parameters documented during the two phases 
are summarised in Table 3. Headaches were more frequent 
during the individualized phase (8 vs 5 episodes; P = 0.04). 
There was no difference between the two phases on intra- 
and postdialytic symptoms (cramps, hypotension and 
intradialytic hypertension).
DIScUSSION
Our study has revealed that isonatraemic haemodialysis 
had no significant effect on IDWG, pre-dialysis BP and 
intradialytic BP. Post-dialysis systolic BP was significantly 
reduced. Our results are similar to those of Thein et al. [15] 
but differ from other studies. Aramreddy [16] reported a 
significant reduction of IDWG after a decrease in Na+ 
dialysate by 2 mmol/L, and Elshahawy et al. [17] found that 
the individualization of Na+ dialysate was associated with a 
decrease of IDWG and better BP control. This effect was 
also reported in the DISO trial [18]. 
Several studies have reported reductions of predialytic 
systolic BP and non-significant reductions in postdialytic 
isonatraemic haemodialysis in the management of salt and water overload.
Figure 2.  Distribution of mid-week predialytic measure-
ments of serum na+ concentration. 





















Figure 3.  Distribution of patients according to serum  
na+ set points. 
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table 1.  Baseline characteristics of patients (n = 32). 
Mean ± standard deviation
Age (years) 55.5 ± 12.1
Dialysis duration (months) 104 ± 43
Dry weight (kg) 63.6 ± 17.0
IDWG (kg) 1.6 ± 0.6
Haemoglobin (g/dL) 10.1 ± 2.5
Haematocrit (%) 31.9 ± 7.2
count (%)
Sex F 15 (46.9)
M 17 (53.1)
Primary kidney disease Hypertension 15 (46.9)
Unknown 8 (25.0)
Chronic glomerulonephritis 7 (21.9)
Postpartum kidney failure 1 (3.1)
Adult polycystic kidney disease 1 (3.1)
Comorbid conditions Pulmonary tuberculosis 2 (6.3)
Other 3 (9.4)
Vascular access Distal arteriovenous fistula 18 (56.3)
Proximal arteriovenous fistula 10 (31.2)
Tunnelled catheter 4 (12.5)
Clinical Residual urine output 9 (28.1)
Intradialytic hypotension 4 (12.5)
Medications ARBs 10 (31.2)
ACEi 8 (25.0)
Calcium channel blockers 3 (9.4)
Beta blockers 4 (12.5)
Rilmenidine 3 (9.4)
Calcium supplementation 5 (15.6)
Vitamin D supplementation 5 (15.6)
Erythropoietin 3 (9.3)
PPIs 2 (6.3)
Intravenous iron therapy 2 (6.3)
NSAIDs 1 (3.1)
Abbreviations: ACEi, angiotensin conversion enzyme inhibitors; ARBs, angiotensin receptor blockers; PPIs, proton pump inhibitors; NSAIDs, non-steroidal anti-inflammatory 
drugs; IDWG = interdialytic weight gain; Other, sickle cell anaemia, autoimmune haemolytic anaemia and peptic ulcer disease.
systolic BP [10,17]. The reduction in BP has been reported 
by other studies where Na+ dialysate was reduced without 
being isonatraemic [11,15]. The improvement in BP is 
linked to the reduction of IDWG. However, we did not 
observe a significant decrease in IDWG. This suggests that 
the beneficial effect on BP of isonatraemic haemodialysis 
may not be related solely to blood volume control.
In our study, the mean predialytic serum Na+ concentration 
was 135.8 mmol/L. This is similar to that reported by De 
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table 2.  effect of isonatraemic haemodialysis on quantitative parameters.
control phase individualized phase P value
Predialytic parameters 
Weight (kg) 64.3 ± 16.9 65.2 ± 17 0.52
IDWG (kg) [%] 1.9 ± 1.0 [3.1] 1.8 ± 1.1 [2.9] 0.75
Systolic BP (mmHg) 144 ± 25 136 ± 29 0.28
Diastolic BP (mmHg) 88 ± 17 78 ± 16 0.51
intradialytic parameters 
Systolic BP (mmHg) 141 ± 56.0 140 ± 30 0.99
Diastolic BP (mmHg) 79 ± 16 77 ± 16 0.98
Postdialytic parameters 
Weight (kg) 63.0 ± 16.8 62.5 ± 16.9 0.90
Ultrafiltration volume (L) 1.9 ± 0.7 1.8 ± 0.7 0.70
Systolic BP (mmHg) 148 ± 31 135 ± 32 0.04
Diastolic BP (mmHg) 84 ± 16 79 ± 18 0.14
Abbreviations: IDWG, interdialytic weight gain.
table 3.  effect of isonatraemic haemodialysis on qualitative parameters. Proportions are the ratio of the counts of each event to the 
number of dialysis sessions in the phase (288 sessions)..
control phase individualized phase P value
Predialytic parameters, n (%) 
Headaches 5 (2) 8 (4) 0.04
Tiredness 25 (10) 20 (10)
intradialytic parameters, n (%) 
Muscle cramps 12 (5) 8 (4) 0.80
Intradialytic hypotension 4 (1) 3 (2) 0.75
Intradialytic hypertension 11 (4) 10 (5) 0.50
Postdialytic parameters, n (%) 
Precordial pain 1 (0) 0 (0)
Headaches 3 (1) 2 (1)
Muscle cramps 6 (2) 4 (2)
Tiredness 3 (1) 2 (1) 0.65
Paula et al. (134.0 mmol/L) [10] and Aramreddy et al. 
(135.5 mmol/L) [16]. In the study by Radhika et al. [18], 
mean predialytic Na+ concentration was higher (138.7 
mmol/L). Forty-one percent of our patients had an SP of 
135–136 mmol/L and 72% had an SP <136 mmol/L. The 
mean SP was lower than the Na+ concentration of the 
standard dialysate used in our haemodialysis units (135.8 
vs 138 mmol/L). This dialysate solution is therefore hyper-
natraemic for most patients and would predispose to salt 
and water overload.
Apart from the headaches that were more frequent in the 
individualized phase, isonatraemic haemodialysis was well 
tolerated. This f inding is corroborated by several other 
studies [16,18]. In an older study, De Paula et al. noted 
better tolerance with a significant reduction in intradialytic 
hypotension [10]. This effect of isonatraemic haemodialysis 
might be related to better volume control with a reduction 
in UF volumes.
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Equipping our haemodialysis units with machines able to 
perform online measurement of Na+ concentration or 
conductivity would seem to be the best way to demonstrate 
the clinical benefits of isonatraemic haemodialysis in its 
isoconductive form. Isonatraemic haemodialysis must be 
integrated into the therapeutic arsenal, which would also 
include patient education on salt and water intake.
The relatively small sample population and the short 
duration were limitations of our study. The benefits of 
isonatraemic haemodialysis can be delayed, occurring 
months after starting the intervention.
cONcLUSIONS
IDWG as well as pre- and intradialytic BP were unaffected 
by isonatraemic haemodialysis, whereas postdialytic BP 
was significantly reduced. This is a well-tolerated modality. 
Upgrading haemodialysis machines to measure conductivity 
in real time would provide the optimal conditions for 
performing isonatric haemodialysis.
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